Why Cardinal Health, Inc. (CAH) stock moved
Cardinal Health, Inc. (CAH) shares rose 0.1% to $226.05 as of July 21, 2026, a slight gain from the prior close of $225.75. BestStocks flagged the session as a major change for CAH. Below, we break down what changed for CAH, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CAH climbed 0.1% to $226.05
Cardinal Health (CAH) rose +1.00% to $241.34 from $238.94 in intraday trading. The stock is described as gaining attention for strong performance and potential undervaluation in the healthcare sector, per Yahoo Finance. Volume data remain unreliable 39 minutes into the session. Monitor for Cardinal Health earnings reports, analyst rating or price-target revisions, or healthcare sector developments that may clarify the move once confirmed at market close.
What it means for Cardinal Health, Inc. investors
For Cardinal Health, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.1% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $255.13, implying +12.9% upside from $226.05. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 21 days out, the next report is the most likely near-term test of the move.
CAH price reaction
CAH last traded at $226.05, up $0.30 (+0.13%) from the previous close of $225.75. The session traded on 0.1× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $222.74 and $239.71, and it currently sits about 20% of the way up that band.
Bullish and bearish analyst opinions on Cardinal Health, Inc. (CAH)
The consensus analyst price target on Cardinal Health, Inc. (CAH) is $255.13, 12.9% above the recent $226.05. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CAH line up.
The bullish case
- Wall Street's consensus price target of $255.13 implies +12.9% upside from $226.05.
- The Street's most bullish target is $275.00 (+21.7%).
- Positive 0.1% session move.
- Positive price momentum.
The bearish case
- The bearish case is comparatively thin on recent signals; the main risk is that the climb toward the $255.13 consensus target has to be earned, and any of the risks BestStocks tracks could weigh on the shares.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CAH
Frequently asked questions about CAH
Why did Cardinal Health, Inc. (CAH) stock move?
CAH rose 0.1% to $226.05. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CAH stock rise?
CAH gained 0.13% ($0.30) versus the prior close of $225.75, last trading at $226.05 on 0.1× average volume.
When is Cardinal Health, Inc.'s next earnings date?
CAH's next earnings report is estimated for 2026-08-11 — about 21 days away.
What is the analyst price target for CAH?
The consensus analyst price target for CAH is $255.13, about 12.9% above the current $226.05. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 0 downgrades.
How BestStocks tracks CAH
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CAH-specific materiality thresholds, triggering an evidence check. It draws on 5 tracked change events for CAH, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.